We initially assessed the expression levels of ADAM19 in the transcriptome data of three SSc cohorts, namely the PRSS cohort (GSE130955, comprising 58 SSc patients and 33 healthy controls), and GENISOS cohort (GSE58095, including 59 SSc patients and 43 healthy controls; GSE181549, consisting of 112 SSc patients and 44 healthy controls). Here, ADAM19 is linked to systemic sclerosis.